ES2185452B2 - Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion. - Google Patents

Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.

Info

Publication number
ES2185452B2
ES2185452B2 ES200001952A ES200001952A ES2185452B2 ES 2185452 B2 ES2185452 B2 ES 2185452B2 ES 200001952 A ES200001952 A ES 200001952A ES 200001952 A ES200001952 A ES 200001952A ES 2185452 B2 ES2185452 B2 ES 2185452B2
Authority
ES
Spain
Prior art keywords
fluoxetine
manufacturing process
pharmaceutical composition
coated tablet
dispersable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200001952A
Other languages
English (en)
Other versions
ES2185452A1 (es
Inventor
Sesma Angel Ursua
Congosto Carlos Yanez-Sedeno
De Narvajas Alcalde F Martinez
Oroz Juan Pedro Larumbe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Cinfa SA
Original Assignee
Laboratorios Cinfa SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cinfa SA filed Critical Laboratorios Cinfa SA
Priority to ES200001952A priority Critical patent/ES2185452B2/es
Priority to EP01306472A priority patent/EP1177788B1/en
Priority to DE60131331T priority patent/DE60131331D1/de
Publication of ES2185452A1 publication Critical patent/ES2185452A1/es
Application granted granted Critical
Publication of ES2185452B2 publication Critical patent/ES2185452B2/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricación, del tipo de composición empleada como antidepresivo que contiene fluoxetina, clorhidrato como principio activo y se presenta bajo la forma de un comprimido dispersable, en la que el principio activo está micronizado y su peso está comprendido entre un ocho y un nueve por ciento (8-9%) del peso total del núcleo de la composición; mientras que la humedad del núcleo de la composición está comprendida entre un tres y un cuatro por cien (3-4%) y el núcleo va recubierto por un revestimiento pelicular que comprende un agente filmógeno hidrosoluble y un agente plastificante, representando este recubrimiento pelicular alrededor de un uno por cien (1%) del peso total del comprimido.
ES200001952A 2000-08-01 2000-08-01 Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion. Expired - Fee Related ES2185452B2 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200001952A ES2185452B2 (es) 2000-08-01 2000-08-01 Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
EP01306472A EP1177788B1 (en) 2000-08-01 2001-07-27 Pharmaceutical composition of fluoxetin in coated dispersible tablets and process for its manufacture
DE60131331T DE60131331D1 (de) 2000-08-01 2001-07-27 Fluoxetin-Arzneimittel in Form überzogener dispergierbarer Tabletten sowie Verfahren zu dessen Herstellung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001952A ES2185452B2 (es) 2000-08-01 2000-08-01 Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.

Publications (2)

Publication Number Publication Date
ES2185452A1 ES2185452A1 (es) 2003-04-16
ES2185452B2 true ES2185452B2 (es) 2004-03-16

Family

ID=8494546

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001952A Expired - Fee Related ES2185452B2 (es) 2000-08-01 2000-08-01 Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.

Country Status (3)

Country Link
EP (1) EP1177788B1 (es)
DE (1) DE60131331D1 (es)
ES (1) ES2185452B2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
WO2007098809A1 (en) * 2006-03-03 2007-09-07 Symrise Gmbh & Co. Kg Pressed agglomerates suitable for consumption having retarded aroma release
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP2019519487A (ja) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
CN107334742B (zh) * 2017-08-18 2020-01-31 山东力诺制药有限公司 一种盐酸氟西汀分散片及其制备方法
CN112741819B (zh) * 2020-12-11 2022-07-22 山西仟源医药集团股份有限公司 一种盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA753851B (en) * 1974-08-01 1976-05-26 Ici Ltd Film coating process
US4816298A (en) * 1987-11-27 1989-03-28 The Dow Chemical Company Method of making a granular, cold water dispersible coating composition
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride

Also Published As

Publication number Publication date
EP1177788A3 (en) 2003-01-08
EP1177788A2 (en) 2002-02-06
ES2185452A1 (es) 2003-04-16
EP1177788B1 (en) 2007-11-14
DE60131331D1 (de) 2007-12-27

Similar Documents

Publication Publication Date Title
ES2185452B2 (es) Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
AR053731A1 (es) Aromatizacion de gomas de mascar que contienen farmacos
ES2195342T3 (es) Formulacion farmaceutica de omeprazol.
NO20080002L (no) Formuleringer av konjugerte ostrogener og bazedoxifen
EA200701816A1 (ru) Продукты, включающие микрокапсулы с быстрым высвобождением
CR7500A (es) Formas de dosificacion de azitromicida con efectos secundarios reducidos
WO2008132712A3 (en) Combination pharmaceutical compositions
AR048457A2 (es) Proceso para formar una composicion farmaceutica de topiramato
UY26306A1 (es) Composición para la dosificación oral, de disolución instantanea
DE60116758D1 (de) Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform
ID27504A (id) Formulasi oral baru
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.
BR0309142A (pt) Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permitem a liberação modificada de princìpio(s) ativo(s)
FR2949062B1 (fr) Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
PE20030527A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
MX2007007986A (es) Composiciones para el cuidado oral de oregano y metodos para el uso de las mismas.
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
RS50063B (sr) Oralni farmaceutski preparat sa fungicidnim dejstvom i postupak za njegovo pripremanje
NO20090407L (no) Aerosolformulering for inhalering av beta agonister
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
MX2023002671A (es) Formulaciones agradables.
BRPI0607990A2 (pt) formulação de um aerossol farmacêutico para inaladores dosimetrados pressurizados contendo um agente seqüestrante, uso do agente sequestrante, inalador de dosimetrado pressurizado e método de preenchimento do inalador de aerossol
RS53775B1 (en) SOLID PHARMACEUTICAL PREPARATION
RS53883B1 (en) IMPROVED MEDICAL FORMULATIONS IN THE FORM OF AEROSOL

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030416

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2185452B2

Country of ref document: ES

GC2A Exploitation certificate registered application with search report

Effective date: 20050317

FD2A Announcement of lapse in spain

Effective date: 20180807